Literature DB >> 24311965

Weakly hormone receptor-positive breast cancer and use of adjuvant hormonal therapy.

Cassandra M Lin1, Jasbir Jaswal, Theodore Vandenberg, Alan Tuck, Muriel Brackstone.   

Abstract

Entities:  

Year:  2013        PMID： 24311965      PMCID： PMC3851361          DOI： 10.3747/co.20.1598

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  5 in total

1.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

2.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

3.  Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy.

Authors:  David A L Morgan; Nicholas A Refalo; Kwok Leung Cheung
Journal:  Breast       Date:  2010-12-14       Impact factor: 4.380

Review 4.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Authors:  M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2010-04-19       Impact factor: 44.544

5.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.

Authors:  A Goldhirsch; J N Ingle; R D Gelber; A S Coates; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2009-06-17       Impact factor: 32.976
  5 in total
  3 in total

1.  Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers.

Authors:  Kristen S Purrington; David Gorski; Michael S Simon; Theresa A Hastert; Seongho Kim; Rayna Rosati; Ann G Schwartz; Manohar Ratnam
Journal:  Breast Cancer Res Treat       Date:  2020-03-31       Impact factor: 4.872

Review 2.  Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine.

Authors:  Krysta Mila Coyle; Jeanette E Boudreau; Paola Marcato
Journal:  Biomed Res Int       Date:  2017-06-08       Impact factor: 3.411

3.  Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65.

Authors:  Suzanne C O'Neill; Claudine Isaacs; Filipa Lynce; Deena Mary Atieh Graham; Calvin Chao; Vanessa B Sheppard; Yingjun Zhou; Chunfu Liu; Nandini Selvam; Marc D Schwartz; Arnold L Potosky
Journal:  Breast Cancer Res       Date:  2017-03-31       Impact factor: 6.466
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.